Encompass Health (EHC) reported an insider equity change: director Leslye G. Katz acquired 73 restricted stock units on 10/15/2025 at $0 per unit. The award reflects dividend-equivalent RSUs tied to a $0.19 common stock dividend, calculated using the $123.65 closing price on the payment date. Following the transaction, Katz beneficially owned 47,752 Encompass Health common shares.
Encompass Health (EHC) director Kevin J. O’Connor reported an automatic credit of 14 restricted stock units (RSUs) on 10/15/2025. The award reflects dividend equivalents under outstanding RSU agreements tied to the company’s common stock dividend.
Per the footnote, the number of RSUs credited equals the product of the RSUs held on the dividend record date and the $0.19 per-share dividend, divided by the $123.65 closing price on the dividend payment date. The transaction was recorded at $0. Following this entry, securities beneficially owned were listed as 9,895, held directly.
Encompass Health (EHC) director Form 4: On 10/15/2025, a non-employee director reported two acquisitions. First, 16 restricted stock units were credited at $0 pursuant to dividend-equivalent terms tied to outstanding RSUs. Second, 288 common shares were purchased at a weighted average price of $123.23 in multiple trades ranging from $123.19 to $123.24.
The RSU credit relates to a $0.19 per-share common dividend paid on October 15, 2025, using the closing price of $123.65 to calculate units. The share purchase reflects the Directors Deferred Stock Investment Plan, which uses deferred director fees and reinvested dividends to buy shares in the market. Following these transactions, direct beneficial ownership reported in Table I was 15,085 shares.
Encompass Health (EHC) director Nancy M. Schlichting reported an automatic credit of 33 restricted stock units (RSUs) on 10/15/2025. The award stems from dividend equivalents pursuant to outstanding RSU award agreements, reflecting Encompass Health’s common stock dividend of $0.19 per share and a closing price of $123.65 on the payment date. The transaction is recorded at $0 as it was an accrual, not a market purchase.
Following this transaction, Schlichting beneficially owns 21,219 shares, held directly.
Encompass Health (EHC) director Terrance Williams reported an automatic credit of 23 restricted stock units on 10/15/2025. The award reflects dividend-equivalent RSUs under outstanding agreements, calculated using a $0.19 per-share dividend and the $123.65 closing price on the dividend payment date. The transaction was recorded at $0 per unit. Following this entry, Williams beneficially owned 15,141 securities in direct ownership.
Encompass Health Corporation reported a change on its board of directors. On September 17, 2025, director Patricia Maryland informed the company that she is retiring from the board for health reasons, effective immediately. The filing notes the board’s appreciation for her insights and contributions, as expressed by chairman Greg Carmichael.
Encompass Health Corp provided forward-looking non-GAAP guidance in an Item 7.01 disclosure, projecting net operating revenue of $5,880 million to $5,980 million, Adjusted EBITDA of $1,220 million to $1,250 million, and adjusted earnings per share from continuing operations of $5.12 to $5.34. The company states it does not provide comprehensive GAAP guidance because certain items cannot be reliably predicted, but it estimates 2025 interest expense and amortization of debt discounts and fees of approximately $125 million and amortization of debt-related items of approximately $10 million. The disclosure is furnished under Regulation FD and is not deemed "filed" for Section 18 purposes.
Encompass Health Corp (EHC) insider Patrick W. Tuer, EVP and Chief Operating Officer, reported a sale of 1,020 shares of Encompass Health common stock on 08/27/2025 at a reported price of $123.59 per share. After the transaction, Mr. Tuer beneficially owned 18,846 shares. The Form 4 was signed by an attorney-in-fact, Patrick Darby, on behalf of the reporting person.
Encompass Health Corporation (EHC) Form 144 reports a proposed sale of 1,020 common shares via UBS Financial Services on the NYSE, with an aggregate market value of $126,061.80. The shares were acquired through restricted stock unit vesting in January–February 2023 (individual lots of 218, 290, 233 and 279 shares) and are scheduled for sale on 08/27/2025. The filer certifies no undisclosed material adverse information and provides no reportable sales in the prior three months.
Douglas E. Coltharp, EVP & Chief Financial Officer of Encompass Health Corporation (EHC), reported multiple non‑derivative transactions on 08/21/2025. The filing shows transfers involving common stock: 27,480 shares were disposed of by the reporting person’s spouse and simultaneously 27,480 shares were acquired by an irrevocable trust in which the reporting person is a beneficiary. After these moves the reporting person reports 37,749 shares beneficially owned via spouse and 125,631 shares indirectly held by an irrevocable trust for the benefit of children; the reporting person disclaims beneficial ownership of the spouse‑held shares. The report was signed by an attorney‑in‑fact.